Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...